• FDA accepts new drug application filing for expanded use of Gattex for short bowel syndrome

    6 monthes ago - By Healio

    The FDA has accepted the filing of a new drug application to extend the use of Gattex for injection in children aged 1 to 17 years with short bowel syndrome, according to a company press release.
    Gattex is indicated for adults with SBS who are dependent on parenteral support.
    “The filing acceptance of Shire's supplemental new drug application by the U.S. FDA is an important milestone in our efforts to investigate the use of Gattex as a potential treatment for children with SBS who are dependent on parenteral support,” Howard Mayer, MD, Shire's
    Read more ...